Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Asymchem Laboratories Tianjin Co Ltd
Intangible Assets
Asymchem Laboratories Tianjin Co Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
|
Intangible Assets
¥421.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Intangible Assets
¥362.6m
|
CAGR 3-Years
121%
|
CAGR 5-Years
106%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Intangible Assets
¥6.8B
|
CAGR 3-Years
46%
|
CAGR 5-Years
82%
|
CAGR 10-Years
43%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Intangible Assets
¥797.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Intangible Assets
¥2.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Intangible Assets
¥26.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Asymchem Laboratories Tianjin Co Ltd
Glance View
In the bustling industrial landscape of Tianjin, Asymchem Laboratories stands as a beacon of innovation and precision in the biopharmaceutical world. Founded with a vision to harmonize the intricate processes of pharmaceutical development, Asymchem has evolved into a powerhouse of Contract Development and Manufacturing Organization (CDMO) services. The company provides end-to-end solutions in the pharmaceutical sector, specializing in the synthesis and manufacturing of small molecule active pharmaceutical ingredients (APIs). Their sophisticated laboratories and state-of-the-art production facilities serve a global clientele, demanding not only high-quality standards but also a seamless integration of complex processes—from drug discovery through commercialization. Asymchem's business model thrives on the symbiosis between its technical expertise and the ever-growing demand for innovative pharmaceuticals. They offer a comprehensive suite of services including research and development, process optimization, and full-scale commercial production. The company's revenue streams are tied to its ability to win long-term contracts with major pharmaceutical companies, focusing on creating custom-tailored solutions that expedite the drug development timeline while ensuring compliance with stringent regulatory standards. By aligning their operations with the needs of the biopharmaceutical industry, Asymchem secures its positioning as a key player, propelling forward the possibilities of modern medicine while ensuring sustainable growth in the competitive pharmaceutical manufacturing sector.
See Also
What is Asymchem Laboratories Tianjin Co Ltd's Intangible Assets?
Intangible Assets
421.8m
CNY
Based on the financial report for Dec 31, 2025, Asymchem Laboratories Tianjin Co Ltd's Intangible Assets amounts to 421.8m CNY.
What is Asymchem Laboratories Tianjin Co Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
8%
Over the last year, the Intangible Assets growth was -2%. The average annual Intangible Assets growth rates for Asymchem Laboratories Tianjin Co Ltd have been -4% over the past three years , 8% over the past five years .